TOPSHOT – Pope Leo XIV leads a Holy mass for the beginning of his pontificate, in St Peter’s square in The Vatican on May 18, 2025. (Photo by Alberto PIZZOLI / AFP)
ALBERTO PIZZOLI/AFP via Getty Images
The first physical shipment of Ebola vaccine reached Congolese soil Friday evening — 16,250 doses of Ervebo touching down at N’djili International Airport in Kinshasa — as Pope Leo XIV issued a rare public call for international solidarity the following morning, and the Democratic Republic of Congo reported 5,515 confirmed cases and 2,642 deaths from the deadliest Ebola outbreak in the country’s recorded history. The case fatality ratio has now climbed to nearly 48 percent, meaning almost one in two confirmed patients is dying — not because the Bundibugyo virus has grown more lethal, but because the response system increasingly finds patients only after they have died.
What Landed Friday — and What It Cannot Do Yet
Health Minister Samuel Roger Kamba confirmed the arrival personally on the Kinshasa airport tarmac, describing Ervebo as a vaccine his government has deployed “several times” in previous outbreaks — most extensively during the 2018–2020 DRC Ebola outbreak. He is correct. What he could not confirm is whether it will work against the strain currently killing Congolese citizens.
Ervebo was developed and approved specifically to fight Zaire ebolavirus — the species responsible for the catastrophic 2014–2016 West Africa epidemic and every major DRC outbreak before 2026. The pathogen spreading through Ituri, North Kivu, South Kivu, Haut-Uele, Tshopo, and Bas-Uele provinces this year belongs to a different species: Bundibugyo ebolavirus. At the nucleotide level, Bundibugyo’s genome diverges from Zaire’s by approximately 30 percent — a gap wide enough that the surface glycoprotein the virus uses to enter human cells differs substantially from the protein that Ervebo trains the immune system to recognize and attack. The WHO’s outbreak situation report confirms the outbreak has now expanded to 54 health zones across those six provinces.
The World Health Organization’s Technical Advisory Group on candidate vaccine prioritization met on July 31 and reversed its May guidance — concluding that the available evidence supports both a Phase 3 clinical trial and expedited stockpile deployment. The evidence it reviewed included animal data showing three of four Ervebo-vaccinated macaques surviving Bundibugyo exposure versus one of four controls, and the surveillance observation that zero vaccinated individuals had died among 242 confirmed fatalities with known vaccination histories. Africa CDC’s three-month outbreak statement explicitly acknowledges that the second finding carries “substantial survivor, ascertainment and confounding biases,” since vaccinated individuals are disproportionately healthcare workers with direct treatment-center access.
Of the 70,000 doses the WHO and International Coordinating Group on Vaccine Provision allocated on August 20, 20,000 are designated for a randomized Phase 3 clinical trial to determine whether Ervebo actually protects humans against Bundibugyo. The remaining 50,000 will go to frontline health workers — not to the general affected population — as a precautionary measure pending trial results. Additional doses are expected in the coming days.
Why the Vaccine’s Arrival Is a Wager, Not a Victory
Deploying a vaccine with unproven cross-protection into a high-distrust community is not the same problem as deploying a vaccine with proven efficacy. It is a more complex one.
Abdulsalami Nasidi, a public health consultant who helped establish the Africa Centres for Disease Control and Prevention, told Al Jazeera that the outbreak is “getting out of hand,” blaming poor infection control and trust deficits for continued transmission. The same community trust gap that prevents contact tracers from finding cases before they die also determines whether a vaccine rollout succeeds.
Ring vaccination — the strategy used successfully to contain prior DRC outbreaks with Ervebo — works by immunizing all identified contacts of confirmed cases plus the contacts of those contacts, creating a protected barrier around active transmission chains. It requires two things: first, an effective vaccine; second, a contact tracing system capable of identifying who those contacts are. The current outbreak has contact tracing that covers about 82.9 percent of identified contacts, a dramatic improvement from the 30 percent reported in June and the collapse to 10 percent reported in early August. Al Jazeera reported the figure above 85 percent as of August 24 — the trajectory is improving. But the WHO considers 90 to 95 percent the minimum threshold to interrupt transmission in an Ebola emergency, and even at the current improved rate, contacts are being missed.
If Ervebo provides cross-protection — and the Phase 3 trial data, still months away, will ultimately answer that question — ring vaccination could break transmission chains that contact tracing cannot reach: the contacts who are never identified before they become symptomatic. If it does not provide adequate cross-protection, the WHO and DRC government will have deployed a vaccine that offers false assurance to communities already deeply skeptical of outside health workers, potentially making the next campaign harder to execute.
“This is no longer just a national or regional issue; it is a global issue,” Nasidi said. “If it spreads to neighbouring places with lower immunity, it will be a disaster.”
Pope Leo XIV Calls for Community-Centered Global Response
At his Sunday Angelus address in St. Peter’s Square, Pope Leo XIV offered the most prominent international moral intervention the outbreak has received since it was declared a Public Health Emergency of International Concern in May. Speaking to tens of thousands of pilgrims gathered at the Vatican, the pontiff delivered a call for solidarity that public health officials have largely echoed in private, but that has rarely received this level of global moral framing.
“In my prayers, I often remember the Democratic Republic of the Congo, particularly in light of the spread of the Ebola epidemic, which is sadly claiming many lives,” the pontiff said, in remarks confirmed by EWTN News. “I encourage on the part of the international community a response that also involves local communities in efforts of prevention, so that many human lives may be saved.”
The appeal — delivered by a pope who visited Africa in April — was notable for its specific emphasis on grassroots community involvement. That framing echoes a message public health officials have been making for months: the outbreak’s most entrenched drivers are not medical, they are social. Armed groups in Ituri Province block treatment teams from reaching communities. Traditional healers continue to treat patients who would otherwise be identified and isolated. Burial practices that the virus makes deadly persist in areas where communities do not trust that government response teams are acting in their interests. No vaccine shipment changes any of those conditions.
The papal call joined a chorus of escalating warnings from international health leadership. UN Senior Ebola Coordinator Julien Harneis warned Friday that the outbreak is spreading exponentially without adequate control and called explicitly for more protective equipment for frontline workers, timely wage payment, and access to rapid diagnosis for any health worker who falls ill. WHO Director-General Tedros Adhanom Ghebreyesus has said the epidemic is on track to eclipse the 2014–2016 West Africa outbreak, which killed more than 11,000 people across Guinea, Liberia, and Sierra Leone.
Health Workers on the Front Line — and Under Attack
The human cost among those fighting the outbreak is one of the most acute dimensions of the crisis and one of the most direct arguments for the 50,000-dose frontline deployment. About 160 health workers have contracted Ebola during this outbreak, and approximately 45 have died, according to DRC outbreak data. That toll is not incidental: it represents the systematic destruction of the response system’s most irreplaceable resource.
“When we go door to door, we don’t have protective equipment, like boots, disinfectant and other supplies, even though we are at risk,” community health worker Ana Ndroy Kasime, deployed in Nizi, Ituri, told the Associated Press. “We buy disinfectant with our own money.”
Health workers staged repeated strikes at facilities including the Elikya Ebola Treatment Center in Bunia and Bunia General Hospital — not over grievances unrelated to the outbreak, but over unpaid wages from the government payroll system. A treatment center whose staff walk off the job cannot isolate patients or trace contacts. The wage failure is not a labor dispute separated from the epidemiological trajectory; it is a containment mechanism failing in real time.
The international response has responded to the funding emergency with pledges, though not yet with adequate disbursements. The WHO and Africa CDC’s joint six-month Continental Preparedness and Response Plan sought $518 million to fund operations through November 2026; as of August 12, approximately $264 million — about half — had been disbursed, according to the WHO’s emergency situation page. The United States committed $242 million in bilateral assistance. The United Kingdom pledged up to £20 million in additional support. The European Union committed €15 million. Gavi, which maintains the global Ervebo stockpile of 500,000 doses, committed $7 million for the dose shipment and an additional $6 million to support vaccination efforts in high-risk areas, as documented in the ICG allocation announcement. Africa CDC Director-General Dr. Jean Kaseya has estimated the true cost of an adequate response at $1.4 billion through November.
What the Bundibugyo Strain Makes Uniquely Difficult
The biology of the outbreak explains why the tools that ended prior crises are unavailable here. Bundibugyo ebolavirus is one of four Orthoebolavirus species capable of causing severe hemorrhagic fever in humans; the other three are Zaire, Sudan, and Taï Forest. Each species expresses a distinct surface glycoprotein — a heavily glycosylated class I viral fusion protein consisting of two subunits, GP1 (receptor-binding) and GP2 (membrane fusion). GP1 attaches the virus to host cells; GP2 triggers viral membrane fusion for infection. Because the antibodies any vaccine generates are specific to the GP architecture they were trained against, vaccines approved for one species offer uncertain, and potentially inadequate, protection against another.
The two prior Bundibugyo outbreaks — Uganda in 2007–2008 (149 confirmed cases) and DRC in 2012 (57 confirmed cases) — were contained too quickly to generate the commercial investment required for clinical development of a Bundibugyo-specific vaccine. Two Bundibugyo-specific candidates are now in Phase 1 human safety trials: Oxford University’s ChAdOx1 BDBV, whose first volunteer was vaccinated July 24, and Moderna’s mRNA-1469, whose Canadian Phase 1 trial launched on August 4. Neither can produce deployable doses for this outbreak — Phase 1 assesses safety, not efficacy, and Phases 2 and 3 are required before authorization. Their significance is for the next Bundibugyo emergency.
The outbreak’s concentration in Ituri Province, which accounts for approximately 90 percent of confirmed cases, reflects the structural geography of the crisis. Ituri is a conflict zone — mining operations for gold, tin, tungsten, and tantalum have driven population movement and armed group activity for decades. Allied Democratic Forces fighters linked to ISIL and local ethnic militias have attacked health facilities and blocked contact tracing teams. In Rwampara, protesters burned Ebola treatment tents earlier in the outbreak. These are not random security events; they systematically destroy the contact lists that ring vaccination and contact monitoring depend on.
Despite those barriers, meaningful progress has been made in pockets. Uganda successfully declared itself Ebola-free on July 28, after 74 days and 20 confirmed cases — all traced to importation events from DRC — with zero community spread. In Uganda’s capital Kampala, the response traced every confirmed case to a documented source, contained it, and never lost control of transmission chains. Several health zones in DRC’s Ituri and South Kivu have also interrupted transmission, demonstrating, as the WHO noted this week, that “rapid detection, decisive leadership, and community cooperation can break the chain of transmission.”
What Contact Tracing Numbers Mean — and Why 82.9 Percent Is Not Enough
Contact tracing is the backbone of every Ebola outbreak response, and its performance during this crisis has been the single most consequential variable in determining who lives and who dies. Bundibugyo has a maximum incubation period of 21 days, meaning every person identified as a contact of a confirmed patient must be monitored daily for three weeks to confirm they have not been infected. Any contact not found within that window may become a confirmed case that produces additional contacts that the system also cannot find.
In early June, the DRC response was tracing an estimated 30 percent of identified contacts — meaning seven in ten chains of transmission were going undetected. By August 20, the European Centre for Disease Prevention and Control reported 82.9 percent of identified contacts under follow-up. That improvement is real, significant, and has been recognized by international health officials as evidence that the surveillance system is recovering.
But the WHO’s minimum threshold for containing an Ebola outbreak is 90 to 95 percent. At 82.9 percent, one in six identified contacts is still being missed. And “identified contacts” is itself a constrained universe — it does not include the contacts the system never identified in the first place, the transmission chains that were never found because the original cases died in their communities before anyone tested them.
The DRC government launched a “Congo River Without Ebola” initiative on August 20, targeting surveillance along the Congo River waterway connecting Kisangani in Tshopo Province to Kinshasa — a critical logistical corridor whose movement patterns the existing surveillance system does not adequately cover, according to WHO outbreak reporting. President Félix-Antoine Tshisekedi’s “One Response” restructuring, announced August 5, centers village-level community health workers as the primary interface between communities and the response — the structural fix for the trust deficit that Nasidi and international health officials have repeatedly identified as the outbreak’s most persistent driver.
What Americans Need to Know Right Now
Bundibugyo ebolavirus transmits only through direct contact with the bodily fluids of a person who is visibly ill or has died from the disease — not through the air, not through casual contact. Three American citizens working with humanitarian organizations in DRC have tested positive during this outbreak; all were medically evacuated to Germany for treatment, per the ECDC epidemiological update. The CDC currently maintains a Level 4 Avoid All Travel advisory for Ituri and North Kivu provinces, and a Level 3 Reconsider Nonessential Travel advisory for Haut-Uele and Tshopo provinces.
Anyone who has been in DRC’s affected provinces within the past 21 days should monitor daily for fever, severe headache, muscle pain, vomiting, diarrhea, or unexplained bleeding. If any symptom develops, call a healthcare provider before visiting a clinic or emergency room, disclose your travel history, and avoid public transit. The CDC maintains enhanced health screening at designated airports for returning travelers from affected areas. The Ervebo vaccine doses deployed in DRC are not available to the general American public, and an Ervebo vaccination received in prior Zaire-outbreak prevention campaigns would offer at best partial and unproven cross-protection against the current strain.
The world’s window to prevent this outbreak from surpassing the 2014–2016 West Africa crisis’s 28,616 cases and 11,310 deaths is still open — but it is narrowing at a rate Africa CDC estimates as one death every 30 minutes. Whether the vaccine, the community trust effort, and the funding can converge fast enough is the question the coming weeks will begin to answer.
Currency conversions in this article are approximate, based on exchange rates at time of publication.
Frequently Asked QuestionsDoes the Ervebo vaccine protect against the Bundibugyo strain driving this outbreak?
The honest answer is: possibly, but not yet proven in humans. Ervebo was approved for Zaire ebolavirus, whose glycoprotein differs from Bundibugyo’s by approximately 30 percent at the nucleotide level. WHO originally recommended against its use for Bundibugyo patients in May 2026. That guidance was reversed by August after animal studies showed three of four Ervebo-vaccinated macaques surviving Bundibugyo exposure, and surveillance data showed zero vaccinated individuals dying among 242 confirmed fatalities with known vaccination histories. But Africa CDC explicitly acknowledges those observational findings are subject to substantial bias — vaccinated individuals are mostly healthcare workers with direct treatment access. A WHO-sponsored Phase 3 randomized clinical trial — using 20,000 of the 70,000 allocated doses — is now the mechanism for getting a real answer. Results will not be available in time to alter this outbreak’s trajectory.
Why has the Ebola case fatality ratio climbed from 20 percent in June to nearly 48 percent now?
The virus has not changed. The response system’s ability to reach patients before they die has deteriorated as the outbreak outgrew its containment infrastructure. Ebola’s primary killer is dehydration, electrolyte loss, and immune system collapse — not a toxin the body cannot survive. Patients who reach a treatment center early enough to receive intravenous fluids and electrolyte management have a meaningfully better chance of survival. A contact tracing system that misses most of its cases — and finds others only after they die in their communities — systematically excludes the patients with the best survival odds from the care that could help them. MSF’s Thomas Parisch described this directly in August: cases are still being “detected very late, when treatment is less likely to succeed.” The rising case fatality ratio is a population-level measure of that operational failure.
What is Pope Leo XIV specifically calling for — and why does community involvement matter?
In his August 23 Angelus address, Pope Leo XIV called for an international response that “also involves local communities in prevention efforts” — not just top-down institutional deployment of foreign health workers. That emphasis on community involvement reflects a lesson that international health officials have been articulating since early in this outbreak: the barriers to containment in eastern DRC are social and political as much as medical. Armed groups block treatment teams. Misinformation leads families to hide sick relatives. Traditional healers see patients before hospitals do. No vaccine shipment changes those dynamics. What changes them — when anything does — is building trust through community health workers who are from the affected areas, speak local languages, and are seen by residents as neighbors rather than outsiders with unknown agendas.
Should Americans be worried about Ebola reaching the United States?
The risk to the general American public is low. Bundibugyo ebolavirus does not spread through the air or through casual contact; it requires direct exposure to the bodily fluids of a person who is visibly ill or recently deceased. The WHO and ECDC both assess the global public risk as low. Three American citizens have been infected during this outbreak — all were humanitarian workers with direct patient exposure in DRC, and all were medically evacuated for treatment. For Americans who have not traveled to DRC’s affected provinces, the practical risk is negligible. For Americans who have recently returned from those provinces, the 21-day monitoring protocol described above is the appropriate precaution: watch for fever, muscle pain, vomiting, diarrhea, or unexplained bleeding, and call a healthcare provider before going to a clinic if any symptom appears.